Document is current
Any future updates will be listed below
-
Authors
Bayle, Arnaud https://orcid.org/0000-0002-2150-7906
Droin, N.
Besse, B.
Zou, Z.
Boursin, Y.
Rissel, S.
Solary, E.
Lacroix, L.
Rouleau, E.
Borget, I.
Bonastre, J.
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-IBHU-0001)
- License Information
-
More Information
Article History
Received: 23 December 2019
Accepted: 16 March 2021
First Online: 25 March 2021
Declarations
:
: Arnaud Bayle: None. Nathalie Droin: None. Benjamin Besse: Sponsored Research at Gustave Roussy Cancer Center: Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma. Zou Zhaomin: None. Yannick Boursin: None. Simon Rissel: None. Eric Solary: None. Ludovic Lacroix: Sponsored Research at Gustave Roussy Cancer Center: Abbott, Astrazeneca, Bayer, Beckman, Boeringer, BMS, Illumina, Genomic Health, Myriad, Novartis, Pfizer, Roche, Siemens, Thermofisher, VelaDx. Etienne Rouleau: AstraZeneca: Consulting fees—Travel, BMS: Consulting fees—Travel, Roche: consulting fees. Isabelle Borget: Roche, merck, Novartis, Janssen: consulting fees. Julia Bonastre: BMS: Travel for attending to Congress, consulting fees; MSD: consulting fees.
